subsequent cell death response (Tann et al., 2011; Guicciardi et al., 2013; Virag et al., 2013; Dorn, 2013). In the current experimental model, early oxidant-mediated mitochondrial PARP1 activation, as well as other mitochondrial events, such as a progressive mitochondrial oxidant production (Fig. 2A) and mitochondrial electron transport defects (Fig. 11), probably contribute to the cell death. The results of the current research demonstrate that these processes are attenuated by blocking the early-onset PKA activation and the subsequent PARP1 activation. The working model outlined in Fig. 12 shows one possible interpretation of the findings of the current report: the cAMP/PKA axis is stimulated by β-adrenoceptor agonists (such as isoproterenol), cAMP analogs (such as 8-bromo-cAMP), and by adenylyl cyclase activators (such as forskolin), leading to mitochondrial PARP1 phosphorylation and increased PARP activity. Moreover, the cAMP/PKA axis is inhibited by β-adrenoceptor antagonists (such as propranolol), by adenylyl cyclase inhibitor (such as DDA) and by inhibition/downregulation of PKA (by the pharmacological inhibitor Rp-cAMP or by genetic silencing of PKA) leading to the inhibition of mitochondrial PARP1 phosphorylation and decreased PARP activity. In the Fig. 12, mitochondrial PKA is shown to be stimulated by cytosolic cAMP. It must be pointed out that multiple lines of data indicate that the cytosolic and mitochondrial cAMP pools do not communicate in most cases. At the same time, several sets of data also indicate that cell membrane and cytosolic signals can elevate intramitochondrial PKA activity, followed by phosphorylation of intramitochondrial proteins (reviewed in Lefkimmiatis and Zaccolo, 2014). Yet another possibility may be the extramitochondrial phosphorylation of PARP1, followed by its transport into the mitochondria, even though the early time course of extranuclear PARP1 phosphorylation (see Fig. 9) tends to speak against this possibility.

Although many additional details of the underlying mechanisms remain to be explored, the current findings may have implications for a number of cellular processes that are known to be regulated by PARP1, including cellular metabolism and DNA repair, given the fact that both of these processes can be regulated by the β-adrenoceptor/cAMP system (Carlucci et al., 2008; Cho and Juhnn, 2012; Valsecchi et al., 2013; Lefkimmiatis and Zaccolo, 2014). However, these aspects remain to be directly investigated in further studies. The current findings may also provide a mechanistic explanation for our previously observed clinical/translational findings (Olah et al., 2011) showing that treatment of patients with severe burn injury with propranolol suppresses PARP1 activation in endothelial cells and tissue-resident mononuclear cells. Further studies are needed to determine whether modulation of PARP1 phosphorylation and its consequent catalytic activity by various drugs targeting the β-adrenoceptor/cAMP/PKA system may be used for therapeutic modulation of PARP1 in various pathophysiologic conditions associated with oxidative stress.

Acknowledgments

The authors thank Drs. Haag and Luo of the Mass Spectrometry Core Facility of UTMB for the mass spectrometry analysis.

Authorship Contributions

Participated in research design: Szabo, Brunyanszki and Szczesny.
Conducted experiments: Brunyanszki, Coletta, Oláh, Szczesny.
Performed data analysis: Brunyanszki, Szczesny.
Wrote or contributed to the writing of the manuscript: Szabo, Brunyanszki, Szczesny.

References

Alamdary SZ, Digaleh H, and Khodagholi F (2013) Dual contradictory effect of H-89 on neuronal retraction, death and inflammation in differentiated PC12 cells subjected to oxidative stress. *J Mol Neurosci* **51**:1030–1037.
Bürkle A and Virág L (2013) Poly(ADP-ribose): PARadigms and PARadoxes. *Mol Aspects Med* **34**:1046–1065.
Carlucci A, Lignitto L, and Feliciello A (2008) Control of mitochondria dynamics and oxidative metabolism by cAMP, AKAPs and the proteasome. *Trends Cell Biol* **18**: 604–613.
Chen G, Pekary AE, Sugawara M, and Hershman JM (1993) Effect of exogenous hydrogen peroxide on iodide transport and iodine organification in FRTL-5 rat thyroid cells. *Acta Endocrinol (Copenh)* **129**:89–96.
Cho EA and Juhnn YS (2012) The cAMP signaling system inhibits the repair of γ-ray-induced DNA damage by promoting Epac1-mediated proteasomal degradation of XRCC1 protein in human lung cancer cells. *Biochem Biophys Res Commun* **422**:256–262.
Curtin NJ and Szabo C (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. *Mol Aspects Med* **34**:1217–1256.
De Vos M, Schreiber V, and Dantzer F (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. *Biochem Pharmacol* **84**: 137–146.
Dorn GW, 2nd (2013) Molecular mechanisms that differentiate apoptosis from programmed necrosis. *Toxicol Pathol* **41**:227–234.
Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, Graham SH, Carcillo JA, Szabó C, and Clark RS (2003) Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD^+ depletion and cell death induced by oxidative stress. *J Biol Chem* **278**:18426–18433.
Gagné JP, Moreel X, Gagné P, Labelle Y, Droit A, Chevalier-Paré M, Bourassa S, McDonald D, Hendzel MJ, and Prigent C et al. (2009) Proteomic investigation of phosphorylation sites in poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase. *J Proteome Res* **8**:1014–1029.
Gancedo JM (2013) Biological roles of cAMP: variations on a theme in the different kingdoms of life. *Biol Rev Camb Philos Soc* **88**:645–668.
Geraets L, Moonen HJ, Wouters EF, Bast A, and Hageman GJ (2006) Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. *Biochem Pharmacol* **72**:902–910.
Gerö D, Szoleczky P, Módis K, Pribis JP, Al-Abed Y, Yang H, Chevan S, Billiar TR, Tracey KJ, and Szabo C (2013a) Identification of pharmacological modulators of HMGB1-induced inflammatory response by cell-based screening. *PLoS ONE* **8**: e65994.
Gerö D, Szoleczky P, Suzuki K, Módis K, Oláh G, oletta C, and Szabo C (2013b) Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction. *Diabetes* **62**:953–964.
Guicciardi ME, Malhi H, Mott JL, and Gores GJ (2013) Apoptosis and necrosis in the liver. *Compr Physiol* **3**:977–1010.
Ha HC and Snyder SH (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. *Proc Natl Acad Sci USA* **96**:13978–13982.
Hegedus C, Lakatos P, Oláh G, Tóth BI, Gergely S, Szabó E, Bíró T, Szabó C, and Virág L (2008) Protein kinase C protects from DNA damage-induced necrotic cell death by inhibiting poly(ADP-ribose) polymerase-1. *FEBS Lett* **582**:1672–1678.
Hottiger MO, Boothby M, Koch-Nolte F, Lüscher B, Martin NM, Plummer R, Wang ZQ, and Ziegler M (2011) Progress in the function and regulation of ADP-Ribosylation. *Sci Signal* **4**:mr5.
Jagtap P, Soriano FG, Virág L, Liaudet L, Mabley J, Szabó E, Haskó G, Marton A, Lorigados CB, and Gallyas F, Jr et al. (2002) Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. *Crit Care Med* **30**:1071–1082.
Jagtap P and Szabó C (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. *Nat Rev Drug Discov* **4**:421–440.
Kauppinen TM, Chan WY, Suh SW, Wiggins AK, Huang EJ, and Swanson RA (2006) Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. *Proc Natl Acad Sci USA* **103**:7136–7141.
Leadsham JE and Gourlay CW (2010) cAMP/PKA signaling balances respiratory activity with mitochondria dependent apoptosis via transcriptional regulation. *BMC Cell Biol* **11**:92.
Lefkimmiatis K, Leronni D, and Hofer AM (2013) The inner and outer compartments of mitochondria are sites of distinct cAMP/PKA signaling dynamics. *J Cell Biol* **202**:453–462.
Lefkimmiatis K and Zaccolo M (2014) cAMP signaling in subcellular compartments. *Pharmacol Ther* DOI: 10.1016/j.pharmthera.2014.03.008 [published ahead of print].
Lopez-Hellin J, Garcia-Arumi E, and Schwartz S (1998) Oxidative stress induces age-dependent changes in lymphocyte protein synthesis and second messenger levels. *Life Sci* **63**:13–21.
Mabley JG, Horváth EM, Murthy KG, Zsengellér Z, Vaslin A, Benko R, Kollai M, and Szabó C (2005) Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. *J Pharmacol Exp Ther* **315**:812–820.
Mabley JG, Wallace R, Pacher P, Murphy K, and Szabó C (2007) Inhibition of poly (adenosine diphosphate-ribose) polymerase by the active form of vitamin D. *Int J Mol Med* **19**:947–952.
Masmoudi A, Islam F, and Mandel P (1988) ADP-ribosylation of highly purified rat brain mitochondria. *J Neurochem* **51**:188–193.
Módis K, Gerő D, Erdélyi K, Szoleczky P, DeWitt D, and Szabo C (2012) Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. *Biochem Pharmacol* **83**:633–643.
Módis K, Gerő D, Stangl R, Rosero O, Szijártó A, Lotz G, Mohácsik P, Szoleczky P, Coletta C, and Szabó C (2013a) Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury. *Int J Mol Med* **31**:437–446.